Publication
A measles virus encoding a CD19/CD3 bispecific T cell engager shows enhanced preclinical anti-BCP-ALL efficacy without significant toxicity
Read publication
Read the publication to explore:
Read publication
- The development of MV-Blina, a recombinant oncolytic measles virus engineered to locally secrete a bispecific T cell engager (bsTE) targeting CD19 and CD3
- How MV-Blina engages and activates T cells, leading to selective leukemia cell death and significant survival benefits in in vitro and in vivo models
- Evidence that MV-Blina does not induce short- or long-term toxicity in in vitro neuronal models encompassing PBMCs or in immunocompromised CD46 transgenic mice
- How ioGlutamatergic Neurons were used
Heinze S, et al.
Molecular Therapy Oncology
2026